Research programme: anti-anthrax monoclonal antibody - iBio

Drug Profile

Research programme: anti-anthrax monoclonal antibody - iBio

Alternative Names: PA monoclonal antibody - iBio; Protective antigen monoclonal antibody - iBio

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator iBio Inc
  • Class Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
  • 25 Feb 2015 iBio has patent protection for Immunoglobulin technology in USA, India, South Korea and Europe
  • 10 Jun 2013 Preclinical trials in Anthrax in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top